# LiMM Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/limm-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.limmtx.com
- Total disclosed funding: $6.1M
- Latest round: Seed (Dec 21, 2020)
- Investors on record: 3

## About

Based in Paris, France, and founded in 2018 by Henrique Veiga-Fernandes, LiMM Therapeutics SA, a.k.a. LiMM Therapeutics operates as a biotechnology company that focuses on developing therapeutic agents and drugs to combat infections or regulate immune reactions. In December 2020, LiMM Therapeutics raised EUR 5 million in seed funding from Portugal Ventures, with participation from Seventure and PME Investimentos.

The company develops solutions by decoding the neuroimmune crosstalk and offering NRILs (Neuronal Reprogrammers of Innate Lymphocytes) to combat inflammatory, infectious, and metabolic diseases. LiMM Therapeutics uncovers the intricate dialogue between neural and immune cells, enhancing immunology. The firm manipulates ILC and neuronal regulation, unveiling new therapeutic pathways for diverse diseases, including oncology.

## Funding rounds

- Seed, Dec 21, 2020, $6.1M — Seventure Partners, Portugal Ventures, PME Investimentos

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Seed
- Portugal Ventures (https://capitalatlas.ai/funds/portugal-ventures) — Seed
- PME Investimentos (https://capitalatlas.ai/funds/pme-investimentos) — Seed